CA2606053A1 - N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress - Google Patents

N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress Download PDF

Info

Publication number
CA2606053A1
CA2606053A1 CA002606053A CA2606053A CA2606053A1 CA 2606053 A1 CA2606053 A1 CA 2606053A1 CA 002606053 A CA002606053 A CA 002606053A CA 2606053 A CA2606053 A CA 2606053A CA 2606053 A1 CA2606053 A1 CA 2606053A1
Authority
CA
Canada
Prior art keywords
nac amide
mixture
compound
nac
derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002606053A
Other languages
English (en)
French (fr)
Inventor
Glenn Goldstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2606053A1 publication Critical patent/CA2606053A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82B—NANOSTRUCTURES FORMED BY MANIPULATION OF INDIVIDUAL ATOMS, MOLECULES, OR LIMITED COLLECTIONS OF ATOMS OR MOLECULES AS DISCRETE UNITS; MANUFACTURE OR TREATMENT THEREOF
    • B82B3/00—Manufacture or treatment of nanostructures by manipulation of individual atoms or molecules, or limited collections of atoms or molecules as discrete units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/17—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/18—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/36—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/40—Y being a hydrogen or a carbon atom
    • C07C323/41—Y being a hydrogen or an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • D—TEXTILES; PAPER
    • D01—NATURAL OR MAN-MADE THREADS OR FIBRES; SPINNING
    • D01D—MECHANICAL METHODS OR APPARATUS IN THE MANUFACTURE OF ARTIFICIAL FILAMENTS, THREADS, FIBRES, BRISTLES OR RIBBONS
    • D01D5/00—Formation of filaments, threads, or the like
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Nanotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Textile Engineering (AREA)
  • AIDS & HIV (AREA)
  • Hospice & Palliative Care (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
CA002606053A 2005-04-21 2006-04-21 N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress Abandoned CA2606053A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US67356105P 2005-04-21 2005-04-21
US60/673,561 2005-04-21
US70596705P 2005-08-05 2005-08-05
US60/705,967 2005-08-05
PCT/US2006/015548 WO2006116353A2 (en) 2005-04-21 2006-04-21 N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress

Publications (1)

Publication Number Publication Date
CA2606053A1 true CA2606053A1 (en) 2006-11-02

Family

ID=37215387

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002606053A Abandoned CA2606053A1 (en) 2005-04-21 2006-04-21 N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress

Country Status (9)

Country Link
US (3) US20090234011A1 (https=)
EP (1) EP1877044A4 (https=)
JP (1) JP2008538586A (https=)
KR (1) KR20080028357A (https=)
AU (1) AU2006238888A1 (https=)
CA (1) CA2606053A1 (https=)
IL (1) IL186684A0 (https=)
RU (1) RU2007143040A (https=)
WO (1) WO2006116353A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8354449B2 (en) 2005-04-21 2013-01-15 Goldstein Glenn A N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
US8993627B2 (en) 2005-04-21 2015-03-31 Sentient Lifesciences, Inc. N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
CN112602724A (zh) * 2020-12-21 2021-04-06 华睿企业管理咨询(衢州)有限公司 一种感染性医疗废物消毒液及其制备方法

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE312103T1 (de) 1999-01-25 2005-12-15 Nat Jewish Med & Res Center Substituierte porphyrine und deren therapeutische verwendungen
WO2007073560A2 (en) * 2005-12-20 2007-06-28 Rnd Pharmaceuticals, Inc. Pharmaceutical compositions and methods of use of highly lipophilic sulfhydryl compounds
JP2010507572A (ja) * 2006-10-23 2010-03-11 ザ メンタル ヘルス リサーチ インスティチュート オブ ビクトリア 併用療法
US20080146579A1 (en) * 2006-12-15 2008-06-19 N.V. Nutricia Treatment of patients with chronic pulmonary diseases and nutritional compositions therefore
CN101636157A (zh) * 2007-01-12 2010-01-27 康乃尔研究基金会有限公司 作为抗菌干预的新型靶的腺苷酰环化酶
CN101680026A (zh) * 2007-01-12 2010-03-24 康乃尔研究基金会有限公司 作为真核病原体感染治疗的新型靶的腺苷酰环化酶
IL188681A0 (en) * 2008-01-09 2008-12-29 Amino Acid Solutions Inc Pharmaceutical compositions and methods utilizing a d-amino acid
CA2724023C (en) * 2008-05-13 2014-02-18 Genmedica Therapeutics Sl Salicylate conjugates useful for treating metabolic disorders
CN102105146A (zh) 2008-05-23 2011-06-22 国立犹太保健医院 用于治疗与暴露于烷化物质有关的损伤的方法
JP2012520342A (ja) * 2009-03-16 2012-09-06 ジェンメディカ・セラピューティックス・ソシエダッド・リミターダ 代謝障害を処置するのに有用な抗炎症剤および抗酸化剤のコンジュゲート
US20100239552A1 (en) * 2009-03-16 2010-09-23 Genmedica Therapeutics Sl Combination Therapies for Treating Metabolic Disorders
JP2011088829A (ja) * 2009-10-20 2011-05-06 Chube Univ 発癌毒性の評価方法及び発癌予防・治療剤
TW201119651A (en) * 2009-10-26 2011-06-16 Lg Life Sciences Ltd Pharmaceutical composition comprising indole compound
US9433596B2 (en) 2010-09-06 2016-09-06 Snu R&Db Foundation Pharmaceutical composition comprising N-acetyl-L-cysteine or its derivatives for treating anxiety disorder
FR2964967A1 (fr) 2010-09-17 2012-03-23 Exsymol Sa Peptidomimetiques derives de la methionine et leur utilisation dans la protection des mitochondries des cellules cutanees
JP5854592B2 (ja) * 2010-11-09 2016-02-09 丸善製薬株式会社 抗酸化剤及び抗炎症剤
US8466197B2 (en) 2010-12-14 2013-06-18 Genmedica Therapeutics Sl Thiocarbonates as anti-inflammatory and antioxidant compounds useful for treating metabolic disorders
ES2893825T3 (es) * 2011-02-04 2022-02-10 Hough Ear Inst Métodos de tratamiento de lesiones cerebrales
WO2013138744A1 (en) * 2012-03-16 2013-09-19 M. Alphabet 1, Llc Compositions for the treatment of skin disorders
WO2013152076A1 (en) * 2012-04-04 2013-10-10 The Brigham And Women's Hospital, Inc. Compositions and methods for treating hypertension
CA2871774C (en) * 2012-04-26 2021-05-18 Sentient Lifesciences, Inc. Use of n-acetylcysteine amide in the treatment of disease and injury
US20130296430A1 (en) * 2012-05-03 2013-11-07 Antonio Hardan Compositions and methods for treating autism and autism spectrum disorder
WO2014011624A2 (en) * 2012-07-10 2014-01-16 Xpd Holdings Llc Stabilized multi-functional antioxidant compounds and methods of use
WO2015006569A2 (en) * 2013-07-10 2015-01-15 Sentient Lifesciences, Inc. Use of n-acetylcysteine amide in the treatment of penetrating head injury
US9630937B2 (en) 2013-11-08 2017-04-25 Promentis Pharmaceuticals, Inc. Substituted N-acetyl-L-cysteine derivatives and related compounds
WO2015112715A1 (en) * 2014-01-24 2015-07-30 Brighton Biotech, Inc. Naca for the treatment of chronic or low impact brian trauma
US20150209309A1 (en) * 2014-01-24 2015-07-30 Brighton Biotech, Inc Naca for the treatment of chronic or acute cognitive dysfunction
US20170049727A1 (en) * 2014-02-12 2017-02-23 Glenn A. Goldstein Use of N-Acetylcysteine Amide in the Treatment of Acquired Immune Deficiency Syndrome and HIV Infection
WO2016044314A1 (en) * 2014-09-15 2016-03-24 Sound Pharmaceuticals Incorporated Methods and compositions for treating psychotic disorders
BR112017009584A2 (pt) * 2014-11-07 2017-12-26 Nacuity Pharmaceuticals Inc tratamento de retinite pigmentosa com n-acetilcisteína amida
US11268964B2 (en) 2014-11-11 2022-03-08 The Johns Hopkins University Biomarkers useful in the treatment of subjects having diseases of the eye
PE20180026A1 (es) 2015-01-27 2018-01-09 Florengale Llc Composicion topica curativa
US20170000747A1 (en) * 2015-06-05 2017-01-05 Glenn A. Goldstein Use of n-acetylcysteine amide in the treatment of acetaminophen overdose
EP3842040B1 (en) * 2016-01-11 2022-03-09 Egetis Therapeutics AB Methods and formulations for treatment of and/or protection against acute liver failure and other hepatotoxic conditions
EP3448378B1 (en) * 2016-04-29 2024-04-17 Ophirex, Inc. Pla2 and hmg-coa inhibitors for treatment of pathological conditions causing hemolysis, cerebral edema, and acute kidney injury
CN111386255B (zh) 2017-09-20 2021-11-23 纳崔泰制药有限公司 用于制备n-乙酰基半胱氨酸酰胺及其衍生物的方法
US11091433B2 (en) 2017-09-20 2021-08-17 Nacuity Pharmaceutials, Inc. Method for preparation of N-acetyl cysteine amide and derivatives thereof
US11548851B2 (en) 2017-09-20 2023-01-10 Nacuity Pharmaceuticals, Inc. Method for preparation of n-acetyl cysteine amide and derivatives thereof
US20240342118A1 (en) * 2017-09-20 2024-10-17 Nacuity Pharmaceuticals, Inc. Method for preparation of n-acetyl cysteine amide or di- n-acetyl cysteine amide and derivatives
US20240368072A1 (en) * 2017-09-20 2024-11-07 Nacuity Pharmaceuticals, Inc. Method for preparation of n-acetyl cysteine amide or di- n-acetyl cysteine amide and derivatives
US20240217927A1 (en) * 2017-11-09 2024-07-04 Nacuity Pharmaceuticals, Inc. Methods of Making Deuterium-Enriched N-Acetylcysteine Amide (D-NACA) and (2R,2R)-3,3-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
US20190135741A1 (en) * 2017-11-09 2019-05-09 Nacuity Pharmaceuticals, Inc. Methods of Making Deuterium-Enriched N-acetylcysteine Amide (D-NACA) and (2R, 2R')-3,3'-Disulfanediyl BIS(2-Acetamidopropanamide) (DINACA) and Using D-NACA and DINACA to Treat Diseases Involving Oxidative Stress
US20190151271A1 (en) * 2017-11-21 2019-05-23 The Johns Hopkins University Compositions and methods for treatment of eye diseases
WO2019107917A1 (ko) * 2017-11-28 2019-06-06 주식회사 셀투인 실시간 글루타치온 측정을 통한 치료용 세포의 품질 측정 방법
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
US11497758B2 (en) 2018-11-15 2022-11-15 Samuel L. Shepherd Method of treating oxidative stress due to radiation exposure
EP3908341A4 (en) * 2019-01-11 2022-03-02 NaCuity Pharmaceuticals, Inc. TREATMENT OF AGE-RELATED MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY WITH N-ACETYLCYSTEINE AMIDE (NACA) OR (2R,2R')-3,3'-BIS(2-ACETAMIDOPROPANAMIDE) DISULFANEDIYL (DINACA)
WO2020146660A1 (en) * 2019-01-11 2020-07-16 Nacuity Pharmaceuticals, Inc. N-acetylcysteine amide (naca) and (2r,2r')-3-3'-disulfanediyl bis (2-acetamidopropanamide) (dinaca) for prevention and treatment of radiation pneumonitis and treatment of pulmonary function in cystic fibrosis
US12458608B2 (en) 2019-01-11 2025-11-04 Nacuity Pharmaceuticals, Inc. N-Acetylcysteine Amide (NACA) and (2R,2R′)-3,3′ disulfanediyl BIS(2-acetamidopropanamide) (DINACA) for the prevention and treatment of radiation dermatitis and skin lightening, skin whitening and skin improvement
CN109758581A (zh) * 2019-02-14 2019-05-17 上海市东方医院（同济大学附属东方医院） 一种抗氧化磁性氧化铁纳米颗粒及其制备方法
WO2020249120A1 (zh) * 2019-06-13 2020-12-17 上海科州药物研发有限公司 氨基硫醇类化合物作为脑神经或心脏保护剂的用途
CA3165422A1 (en) 2019-12-18 2021-06-24 Neuronasal, Inc. Methods of treating brain disorders
CA3167959A1 (en) * 2020-01-24 2021-07-29 Nacuity Pharmaceuticals, Inc. Prodrug for the treatment of disease and injury of oxidative stress
WO2021252378A1 (en) * 2020-06-08 2021-12-16 Nacuity Pharmaceuticals, Inc. Prevention or treatment of covid-19
WO2022011305A2 (en) * 2020-07-09 2022-01-13 Beyond Barriers Therapeutics, Inc. Intranasal administration of an antioxidant compound for treating coronavirus infection
JP2024503174A (ja) * 2020-08-06 2024-01-25 イッサム リサーチ ディベロップメント カンパニー オブ ザ ヘブライ ユニバーシティー オブ エルサレム リミテッド オレイルシステインアミドまたはその誘導体及び治療におけるその使用
EP3960168A1 (en) * 2020-08-28 2022-03-02 Université de Genève Compositions and methods comprising d-cysteine or a derivative thereof
AU2022204064A1 (en) 2021-07-16 2023-02-02 Samuel L. Shepherd Method of treating oxidative stress due to radiation exposure
CN115449065B (zh) * 2022-09-21 2023-09-22 中南大学湘雅医院 一种nac改性血液净化膜及其制备方法
WO2026015776A1 (en) * 2024-07-12 2026-01-15 Nacuity Pharmaceuticals, Inc. Method for preparation of n-acetyl cysteine amide or di- n-acetyl cysteine amide and derivatives

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5696109A (en) * 1992-12-07 1997-12-09 Eukarion, Inc. Synthetic catalytic free radical scavengers useful as antioxidants for prevention and therapy of disease
US5691380A (en) * 1995-06-29 1997-11-25 The Procter & Gamble Company Stable n-acetylcysteine compositions and methods for treating human skin therewith
US5733535A (en) * 1995-10-25 1998-03-31 The Procter & Gamble Co. Topical compositions containing N-acetylcysteine and odor masking materials
US5962421A (en) * 1996-05-16 1999-10-05 Zambon, S.A. Pharmacological association between N-acetylcysteine and levulose for preventing cellular death and related diseases
US6369106B1 (en) * 1996-12-26 2002-04-09 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment of ischemic brain injuries with brain targeted anti oxidant compounds
US5874468A (en) * 1996-12-26 1999-02-23 Yissum Brain targeted low molecular weight hydrophobic antioxidant compounds
US6420429B1 (en) * 1997-12-23 2002-07-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Brain targeted low molecular weight hydrophobic antioxidant compounds
US6719969B1 (en) * 1999-08-09 2004-04-13 The Regents Of The University Of Michigan Treatment of liver disease and injury with CXC chemokines
JP2002226457A (ja) * 2001-02-02 2002-08-14 Ajinomoto Co Inc 新規シスチン誘導体及び炎症因子活性化抑制剤
US6623754B2 (en) * 2001-05-21 2003-09-23 Noveon Ip Holdings Corp. Dosage form of N-acetyl cysteine
WO2003016551A2 (en) * 2001-08-16 2003-02-27 Boyce Thompson Institute For Plant Research, Inc. Novel salicylic acid-binding protein encoding nucleic acid, sabp2, and methods of use thereof
AU2003247144B2 (en) * 2002-08-02 2007-11-29 Mor Research Applications Ltd. Treatment of multiple sclerosis with brain targeted anti oxidant compounds
WO2004095926A2 (en) * 2003-04-28 2004-11-11 Monsanto Technology, Llc Treatment of plants and plant propagation materials with an antioxidant to improve plant health and/or yield
EP1881761A2 (en) 2005-04-21 2008-01-30 Glenn A. Goldstein N-acetylcysteine amide (nac amide) for enhancing plant resistance and tolerance to environmental stress
US20080200548A1 (en) * 2005-04-21 2008-08-21 Goldstein Glenn A N-Acetylcysteine Amide (Nac Amide) for Treatment of Oxidative Stress Associated with Infertility
US20090234011A1 (en) * 2005-04-21 2009-09-17 Goldstein Glenn A N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions associated with oxidative stress

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8354449B2 (en) 2005-04-21 2013-01-15 Goldstein Glenn A N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
US8937099B2 (en) 2005-04-21 2015-01-20 Sentient Lifesciences, Inc. N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
US8993627B2 (en) 2005-04-21 2015-03-31 Sentient Lifesciences, Inc. N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
US9216162B2 (en) 2005-04-21 2015-12-22 Glenn A. Goldstein N-acetylcysteine amide (NAC amide) in the treatment of diseases and conditions associated with oxidative stress
US10869846B2 (en) 2005-04-21 2020-12-22 Sentient Lifesciences, Inc. N-acetylcysteine amide (NAC amide) in the treatment of diseases and conditions associated with oxidative stress
CN112602724A (zh) * 2020-12-21 2021-04-06 华睿企业管理咨询(衢州)有限公司 一种感染性医疗废物消毒液及其制备方法

Also Published As

Publication number Publication date
WO2006116353A2 (en) 2006-11-02
US20100120920A1 (en) 2010-05-13
US8354449B2 (en) 2013-01-15
IL186684A0 (en) 2008-02-09
JP2008538586A (ja) 2008-10-30
AU2006238888A1 (en) 2006-11-02
EP1877044A4 (en) 2009-09-02
EP1877044A2 (en) 2008-01-16
WO2006116353A8 (en) 2008-03-13
US8937099B2 (en) 2015-01-20
KR20080028357A (ko) 2008-03-31
RU2007143040A (ru) 2009-05-27
US20100137441A1 (en) 2010-06-03
US20090234011A1 (en) 2009-09-17
WO2006116353A3 (en) 2007-06-28

Similar Documents

Publication Publication Date Title
US8937099B2 (en) N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
US10869846B2 (en) N-acetylcysteine amide (NAC amide) in the treatment of diseases and conditions associated with oxidative stress
WO2011044230A2 (en) N-acetylcysteine amide (nac amide) for the treatment of diseases and conditions
US6350467B1 (en) Pharmaceutical preparations of glutathione and methods of administration thereof
JP5253750B2 (ja) 免疫系の一般的反応により引き起こされる病態の治療のための医薬組成物
US8487001B2 (en) Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
US6896899B2 (en) Pharmaceutical preparations of glutathione and methods of administration thereof
US6444221B1 (en) Methods of treating chronic inflammatory diseases using carbonyl trapping agents
AU2016228304B2 (en) Isoprenyl compounds and methods thereof
US20140045943A1 (en) Hydroxamic Acid Derivatives, Preparation and Therapeutic Uses Thereof
EP3075248B1 (en) Use of anti-bacterial agents for the treatment of epithelial-related conditions
CN1230178A (zh) 含聚二硫代氨基甲酸酯的大分子和其用于治疗和诊断应用的用途
CN101232877A (zh) 治疗与氧化应激有关的疾病和病症的n-乙酰半胱氨酸酰胺（nac酰胺）
CA2636042A1 (en) Lanthionine-related compounds for the treatment of inflammatory diseases
AU2007215211B2 (en) Methoxypolyethylene glycol thioester chelate and uses thereof
US8871805B2 (en) Compound, composition and uses thereof
US20060154984A1 (en) Therapeutic use of acyl glycerols and the nitrogen- and sulphur- containing analogues thereof
CA2605707A1 (en) Pharmaceutical preparations of glutathione and methods of administration thereof

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20190319